Ovarian Cancer and Cancer Stem Cells-Cellular and Molecular Characteristics, Signaling Pathways, and Usefulness as a Diagnostic Tool in Medicine and Oncology

被引:19
作者
Nowicki, Andrzej [1 ]
Kulus, Magdalena [2 ]
Wieczorkiewicz, Maria [3 ]
Pienkowski, Wojciech [4 ]
Stefanska, Katarzyna [5 ]
Skupin-Mrugalska, Paulina [6 ]
Bryl, Rut [7 ]
Mozdziak, Paul [8 ]
Kempisty, Bartosz [2 ,5 ,7 ,8 ]
Piotrowska-Kempisty, Hanna [1 ,3 ]
机构
[1] Poznan Univ Med Sci, Dept Toxicol, PL-60631 Poznan, Poland
[2] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL-87100 Torun, Poland
[3] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Basic & Preclin Sci, PL-87100 Torun, Poland
[4] Poznan Univ Med Sci, Div Perinatol & Womens Dis, PL-60535 Poznan, Poland
[5] Poznan Univ Med Sci, Dept Histol & Embryol, PL-60781 Poznan, Poland
[6] Poznan Univ Med Sci, Dept Inorgan & Analyt Chem, PL-60780 Poznan, Poland
[7] Poznan Univ Med Sci, Dept Anat, PL-60781 Poznan, Poland
[8] North Carolina State Univ, Dept Poultry Sci, Raleigh, NC 27695 USA
关键词
ovarian cancer; cancer stem cells; molecular markers; ovarian tumor; CORD-STROMAL TUMORS; SELF-RENEWAL; MESENCHYMAL TRANSITION; TARGETED TREATMENT; INITIATING CELLS; DRUG-RESISTANCE; GENE-EXPRESSION; IN-VITRO; IDENTIFICATION; HEDGEHOG;
D O I
10.3390/cancers13164178
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Ovarian cancer is still a high-risk, metastatic disease, often diagnosed at a late stage. Difficulties in its treatment are associated with high resistance to chemotherapy and recurrence. Responsible for the malignant features of cancer are considered to be cancer stem cells (CSCs), which generate new cells by modifying various signaling pathways. Signaling pathways are crucial for the regulation of epithelial-mesenchymal transition, metastasis, and self-renewal of CSCs. New therapies based on the use of inhibitors that block CSC growth and proliferation signals are being investigated. The current histological classification of ovarian tumors, their epidemiology, and the recent knowledge of ovarian CSCs, with particular emphasis on their molecular basis, are important considerations. Despite the increasing development of medicine, ovarian cancer is still a high-risk, metastatic disease that is often diagnosed at a late stage. In addition, difficulties in its treatment are associated with high resistance to chemotherapy and frequent relapse. Cancer stem cells (CSCs), recently attracting significant scientific interest, are considered to be responsible for the malignant features of tumors. CSCs, as the driving force behind tumor development, generate new cells by modifying different signaling pathways. Moreover, investigations on different types of tumors have shown that signaling pathways are key to epithelial-mesenchymal transition (EMT) regulation, metastasis, and self-renewal of CSCs. Based on these established issues, new therapies are being investigated based on the use of inhibitors to block CSC growth and proliferation signals. Many reports indicate that CSC markers play a key role in cancer metastasis, with hopes placed in their targeting to block this process and eliminate relapses. Current histological classification of ovarian tumors, their epidemiology, and the most recent knowledge of ovarian CSCs, with particular emphasis on their molecular background, are important aspects for consideration. Furthermore, the importance of signaling pathways involved in tumor growth, development, and metastasis, is also presented.
引用
收藏
页数:21
相关论文
共 160 条
  • [1] Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
    Abubaker, Khalid
    Latifi, Ardian
    Luwor, Rod
    Nazaretian, Simon
    Zhu, Hongjian
    Quinn, Michael A.
    Thompson, Erik W.
    Findlay, Jock K.
    Ahmed, Nuzhat
    [J]. MOLECULAR CANCER, 2013, 12
  • [2] Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches
    Aguilar-Gallardo, Cristobal
    Cecilia Rutledge, Emily
    Martinez-Arroyo, Ana M.
    Jose Hidalgo, Juan
    Domingo, Santiago
    Simon, Carlos
    [J]. STEM CELL REVIEWS AND REPORTS, 2012, 8 (03) : 994 - 1010
  • [3] Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells
    Ahmed, Nuzhat
    Escalona, Ruth
    Leung, Dilys
    Chan, Emily
    Kannourakis, George
    [J]. SEMINARS IN CANCER BIOLOGY, 2018, 53 : 265 - 281
  • [4] Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets
    Ahmed, Nuzhat
    Abubaker, Khalid
    Findlay, Jock K.
    [J]. MOLECULAR ASPECTS OF MEDICINE, 2014, 39 : 110 - 125
  • [5] Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
    Ahmed, Nuzhat
    Stenvers, Kaye L.
    [J]. FRONTIERS IN ONCOLOGY, 2013, 3
  • [6] Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance
    Ahmed, Nuzhat
    Abubaker, Khalid
    Findlay, Jock
    Quinn, Michael
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (01) : 21 - 34
  • [7] Akbarzadeh Maryam, 2018, Asian Pac J Cancer Prev, V19, P3473
  • [8] Ovarian cancer stem cells: What progress have we made?
    Al-Alem, Linah F.
    Pandya, Unnati M.
    Baker, Andrew T.
    Bellio, Chiara
    Zarrella, Bianca D.
    Clark, Justin
    DiGloria, Celeste M.
    Rueda, Bo R.
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2019, 107 : 92 - 103
  • [9] Prospective identification of tumorigenic breast cancer cells
    Al-Hajj, M
    Wicha, MS
    Benito-Hernandez, A
    Morrison, SJ
    Clarke, MF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) : 3983 - 3988
  • [10] Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance
    Alvero, Ayesha B.
    Chen, Rui
    Fu, Han-Hsuan
    Montagna, Michele
    Schwartz, Peter E.
    Rutherford, Thomas
    Silasi, Dan-Arin
    Steffensen, Karina D.
    Waldstrom, Marianne
    Visintin, Irene
    Mor, Gil
    [J]. CELL CYCLE, 2009, 8 (01) : 158 - 166